ARRAY BIOPHARMA INC.
ARRAY BIOPHARMA INC.
Apertura: -
Cambio neto: -
Volumen: -
Mínimo: -
Máximo: -
Distancia Mín/Máx: -
Tipo: Acciones
Ticker: ARRY
ISIN:

Array BioPharma To Report Financial Results For The First Quarter Of Fiscal 2017 On November 1, 2016

  • 62
Array BioPharma To Report Financial Results For The First Quarter Of Fiscal 2017 On November 1, 2016

PR Newswire

BOULDER, Colo., Oct. 25, 2016 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq:  ARRY) will report financial results for the first quarter of fiscal 2017 and hold a conference call to discuss those results on Tuesday, November 1, 2016. Ron Squarer, Chief Executive Officer, will lead the call.

Date:               

Tuesday, November 1, 2016

Time:              

9:00 a.m. Eastern Time

Toll-Free:        

(844) 464-3927

Toll:                

(765) 507-2598

Pass Code:      

93600421

Webcast, including Replay and Conference Call Slides: 
http://edge.media-server.com/m/p/8qcss7div

About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Five registration studies are currently advancing related to three cancer drugs. These programs include binimetinib (MEK162), encorafenib (LGX818) and selumetinib (AstraZeneca).

CONTACT:       

Tricia Haugeto                          


Array BioPharma Inc.


(303) 386-1193


[email protected]

 

Array BioPharma.

Logo - http://photos.prnewswire.com/prnh/20121029/LA02195LOGO

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/array-biopharma-to-report-financial-results-for-the-first-quarter-of-fiscal-2017-on-november-1-2016-300350249.html

SOURCE Array BioPharma Inc.

PR Newswire
PR Newswire

PR Newswire es un distribuidor de comunicados de prensa con sede en la ciudad de Nueva York. El servicio se creó en 1954 para permitir que las empresas envíen comunicados de prensa electrónicamente a las organizaciones de noticias, al principio utilizando teleimpresores.